Collegium Pharmaceutical, Inc. Operating Expenses
Collegium Pharmaceutical, Inc. (COLL) reported Operating Expenses of $106.59 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-06
- Collegium Pharmaceutical, Inc. operating expenses for the quarter ending 2026-06-30 was $106.59M, a 45.46% increase year-over-year.
- Collegium Pharmaceutical, Inc. operating expenses for the quarter ending 2026-03-31 was $86.35M, a 14.16% increase year-over-year.
- Collegium Pharmaceutical, Inc. operating expenses for the quarter ending 2025-12-31 was $67.62M, a 12.37% increase year-over-year.
- Collegium Pharmaceutical, Inc. operating expenses for the quarter ending 2025-09-30 was $67.08M, a 8.28% increase year-over-year.
- Collegium Pharmaceutical, Inc. operating expenses for fiscal 2025 was $283.62M, a 36.72% increase from fiscal 2024.
- Collegium Pharmaceutical, Inc. operating expenses for fiscal 2024 was $207.45M, a 30.30% increase from fiscal 2023.
- Collegium Pharmaceutical, Inc. operating expenses for fiscal 2023 was $159.21M, a 9.63% decline from fiscal 2022.
- Collegium Pharmaceutical, Inc. operating expenses for fiscal 2022 was $176.17M, a 32.47% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $106.59M 10-Q · filed 2026-08-06 | $192.94M 10-Q · filed 2026-08-06 | $260.56M derived: sum of 3 quarters · filed 2026-08-06 | $327.65M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $86.35M 10-Q · filed 2026-05-07 | $153.97M derived: sum of 2 quarters · filed 2026-05-07 | $221.06M derived: sum of 3 quarters · filed 2026-05-07 | $294.33M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $67.62M 10-K · filed 2026-02-26 | $134.71M derived: sum of 2 quarters · filed 2026-02-26 | $207.98M derived: sum of 3 quarters · filed 2026-08-06 | $283.62M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $67.08M 10-K · filed 2026-02-26 | $140.36M derived: sum of 2 quarters · filed 2026-08-06 | $216.00M 10-Q · filed 2025-11-06 | $276.18M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $73.28M 10-Q · filed 2026-08-06 | $148.92M 10-Q · filed 2026-08-06 | $209.09M derived: sum of 3 quarters · filed 2026-08-06 | $271.05M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $75.64M 10-Q · filed 2026-05-07 | $135.81M derived: sum of 2 quarters · filed 2026-05-07 | $197.77M derived: sum of 3 quarters · filed 2026-05-07 | $241.10M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $60.18M 10-K · filed 2026-02-26 | $122.13M derived: sum of 2 quarters · filed 2026-02-26 | $165.47M derived: sum of 3 quarters · filed 2026-02-26 | $207.45M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $61.95M 10-K · filed 2026-02-26 | $105.29M derived: sum of 2 quarters · filed 2026-02-26 | $147.27M 10-Q · filed 2025-11-06 | $180.21M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-06-30 | $43.34M 10-K · filed 2026-02-26 | $85.32M 10-Q · filed 2025-08-07 | $118.26M derived: sum of 3 quarters · filed 2026-02-26 | $153.56M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-03-31 | $41.98M 10-K · filed 2026-02-26 | $74.92M derived: sum of 2 quarters · filed 2026-02-26 | $110.22M derived: sum of 3 quarters · filed 2026-02-26 | $148.41M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2023-12-31 | $32.94M 10-K · filed 2025-02-27 | $68.24M derived: sum of 2 quarters · filed 2025-02-27 | $106.43M derived: sum of 3 quarters · filed 2025-02-27 | $159.21M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $35.30M 10-K · filed 2025-02-27 | $73.49M derived: sum of 2 quarters · filed 2025-02-27 | $126.27M 10-Q · filed 2024-11-07 | $164.30M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-06-30 | $38.19M 10-K · filed 2025-02-27 | $90.97M 10-Q · filed 2024-08-08 | $129.00M derived: sum of 3 quarters · filed 2025-02-27 | $167.37M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-03-31 | $52.77M 10-K · filed 2025-02-27 | $90.81M derived: sum of 2 quarters · filed 2025-02-27 | $129.18M derived: sum of 3 quarters · filed 2025-02-27 | $170.43M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2022-12-31 | $38.03M 10-K · filed 2024-02-22 | $76.40M derived: sum of 2 quarters · filed 2024-02-22 | $117.66M derived: sum of 3 quarters · filed 2024-02-22 | $176.17M 10-K · filed 2025-02-27 | |
| 2022-09-30 | $38.37M 10-K · filed 2024-02-22 | $79.63M derived: sum of 2 quarters · filed 2024-02-22 | $138.14M 10-Q · filed 2023-11-07 | $170.93M derived: sum of 4 quarters · filed 2024-02-22 | |
| 2022-06-30 | $41.25M 10-K · filed 2024-02-22 | $99.77M 10-Q · filed 2023-08-03 | $132.55M derived: sum of 3 quarters · filed 2024-02-22 | $164.52M derived: sum of 4 quarters · filed 2024-02-22 | |
| 2022-03-31 | $58.51M 10-K · filed 2024-02-22 | $91.30M derived: sum of 2 quarters · filed 2024-02-22 | $123.26M derived: sum of 3 quarters · filed 2024-02-22 | $157.09M derived: sum of 4 quarters · filed 2024-02-22 | |
| 2021-12-31 | $32.79M 10-K · filed 2023-02-23 | $64.75M derived: sum of 2 quarters · filed 2023-02-23 | $98.58M derived: sum of 3 quarters · filed 2023-02-23 | $132.99M 10-K · filed 2024-02-22 | |
| 2021-09-30 | $31.96M 10-K · filed 2023-02-23 | $65.79M derived: sum of 2 quarters · filed 2023-02-23 | $100.20M 10-Q · filed 2022-11-03 | $129.50M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2021-06-30 | $33.83M 10-K · filed 2023-02-23 | $68.24M 10-Q · filed 2022-08-04 | $97.53M derived: sum of 3 quarters · filed 2023-02-23 | $126.10M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2021-03-31 | $34.41M 10-K · filed 2023-02-23 | $63.70M derived: sum of 2 quarters · filed 2023-02-23 | $92.27M derived: sum of 3 quarters · filed 2023-02-23 | $124.08M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2020-12-31 | $29.30M 10-K · filed 2022-02-24 | $57.86M derived: sum of 2 quarters · filed 2022-02-24 | $89.68M derived: sum of 3 quarters · filed 2022-02-24 | $123.60M 10-K · filed 2023-02-23 | |
| 2020-09-30 | $28.57M 10-K · filed 2022-02-24 | $60.38M derived: sum of 2 quarters · filed 2022-02-24 | $94.31M 10-Q · filed 2021-11-04 | $121.80M derived: sum of 4 quarters · filed 2022-02-24 | |
| 2020-06-30 | $31.82M 10-K · filed 2022-02-24 | $65.74M 10-Q · filed 2021-08-05 | $93.23M derived: sum of 3 quarters · filed 2022-02-24 | $125.79M derived: sum of 4 quarters · filed 2022-02-24 | |
| 2020-03-31 | $33.93M 10-K · filed 2022-02-24 | $61.41M derived: sum of 2 quarters · filed 2022-02-24 | $93.98M derived: sum of 3 quarters · filed 2022-02-24 | $125.37M derived: sum of 4 quarters · filed 2022-02-24 | |
| 2019-12-31 | $27.49M 10-K · filed 2021-02-25 | $60.05M derived: sum of 2 quarters · filed 2021-02-25 | $91.44M derived: sum of 3 quarters · filed 2021-02-25 | $126.79M 10-K · filed 2022-02-24 | |
| 2019-09-30 | $32.56M 10-K · filed 2021-02-25 | $63.96M derived: sum of 2 quarters · filed 2021-02-25 | $99.30M 10-Q · filed 2020-11-05 | ||
| 2019-06-30 | $31.39M 10-K · filed 2021-02-25 | $66.74M 10-Q · filed 2020-08-05 | |||
| 2019-03-31 | $35.34M 10-K · filed 2021-02-25 | ||||
| 2018-12-31 | $135.42M 10-K · filed 2021-02-25 | ||||
| 2016-12-31 | $28.88M 10-K · filed 2017-03-10 | $55.73M derived: sum of 2 quarters · filed 2017-03-10 | $80.21M derived: sum of 3 quarters · filed 2017-03-10 | $95.79M 10-K · filed 2017-03-10 | |
| 2016-09-30 | $26.85M 10-K · filed 2017-03-10 | $51.32M derived: sum of 2 quarters · filed 2017-03-10 | $66.91M 10-Q · filed 2016-11-10 | $76.35M derived: sum of 4 quarters · filed 2017-03-10 | |
| 2016-06-30 | $24.47M 10-K · filed 2017-03-10 | $40.06M 10-Q · filed 2016-08-11 | $49.50M derived: sum of 3 quarters · filed 2017-03-10 | $58.76M derived: sum of 4 quarters · filed 2017-03-10 | |
| 2016-03-31 | $15.59M 10-K · filed 2017-03-10 | $25.02M derived: sum of 2 quarters · filed 2017-03-10 | $34.29M derived: sum of 3 quarters · filed 2017-03-10 | $38.86M derived: sum of 4 quarters · filed 2017-03-10 | |
| 2015-12-31 | $9.44M 10-K · filed 2017-03-10 | $18.70M derived: sum of 2 quarters · filed 2017-03-10 | $23.28M derived: sum of 3 quarters · filed 2017-03-10 | $26.91M 10-K · filed 2017-03-10 | |
| 2015-09-30 | $9.27M 10-K · filed 2017-03-10 | $13.84M derived: sum of 2 quarters · filed 2017-03-10 | $17.47M 10-Q · filed 2016-11-10 | $20.80M derived: sum of 4 quarters · filed 2017-03-10 | |
| 2015-06-30 | $4.58M 10-K · filed 2017-03-10 | $8.21M 10-Q · filed 2016-08-11 | $11.53M derived: sum of 3 quarters · filed 2017-03-10 | $18.04M derived: sum of 4 quarters · filed 2017-03-10 | |
| 2015-03-31 | $3.63M 10-K · filed 2017-03-10 | $3.63M 10-Q/A · filed 2015-07-17 | $6.96M derived: sum of 2 quarters · filed 2017-03-10 | $13.46M derived: sum of 3 quarters · filed 2017-03-10 | $17.55M derived: sum of 4 quarters · filed 2017-03-10 |
| 2014-12-31 | $3.33M 10-K · filed 2016-03-18 | $9.83M derived: sum of 2 quarters · filed 2016-03-18 | $13.92M derived: sum of 3 quarters · filed 2016-03-18 | $17.66M 10-K · filed 2017-03-10 | |
| 2014-09-30 | $6.50M 10-K · filed 2016-03-18 | $10.59M derived: sum of 2 quarters · filed 2016-03-18 | $14.34M 10-Q · filed 2015-11-12 | ||
| 2014-06-30 | $4.09M 10-K · filed 2016-03-18 | $7.83M 10-Q · filed 2015-08-12 | |||
| 2014-03-31 | $3.75M 10-K · filed 2016-03-18 | $3.74M 10-Q/A · filed 2015-07-17 | |||
| 2013-12-31 | $16.04M 10-K · filed 2016-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |